Browsing Tag
Nuvalent
4 posts
Nuvalent (NUVL) brings full ALKOVE-1 dataset to ASCO 2026 oral session weeks after neladalkib FDA filing
Nuvalent (NUVL) brings pivotal ALKOVE-1 neladalkib data to ASCO 2026. Here's what the oral session means for its dual NDA strategy and ALK lung cancer treatment.
Nuvalent (NASDAQ: NUVL) sharpens zidesamtinib case at AACR 2026 with post-TKI ROS1 lung cancer data
Nuvalent’s AACR 2026 zidesamtinib data could reshape the ROS1 NSCLC treatment debate ahead of its FDA decision. Read what it means now.
Investors watch Nuvalent ahead of pivotal neladalkib ALKOVE-1 topline data in resistant ALK-positive NSCLC
Nuvalent will unveil pivotal ALKOVE-1 data for neladalkib in TKI-pretreated ALK-positive NSCLC on November 17. Explore why investors believe this readout could redefine targeted lung cancer care.
Nuvalent’s stock jumps 22% after ESMO 2024 – what’s next for this biotech game-changer?
Nuvalent, Inc., a biopharmaceutical company specialising in targeted cancer therapies, has seen its stock price skyrocket following the…